


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-3.47%
-2.66%
-0.94%
+5.46%
VTYX
Ventyx Biosciences Inc.
$14.03
Strengths

Upgraded on attractively valued

Earnings are forecast to grow
VTYX Price Performance
$9.26 (+51.51%)
$7.37 (+90.37%)
$2.46 (+470.33%)
$1.67 (+740.12%)
VTYX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
VTYX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
VTYX Street Sentiment is extremely bullish and have positive views on the near-term outlook
VTYX has Extreme risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels
What is VTYX current stock price?
What are VTYX stock strengths?
What is VTYX Risk Level?
What is VTYX market cap and volume?
What is VTYX current Stock IQ?
Should I buy VTYX stock right now?
Is VTYX a Strong Buy right now?
What does a 'Strong Buy' rating mean for VTYX?
What does a 'Strong Sell' rating mean for VTYX?
What factors influence VTYX's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-3.47%
-2.66%
-0.94%
+5.46%
VTYX
Ventyx Biosciences Inc.
Current Price
$14.03
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

VTYX Price Performance
$9.26 (+51.51%)
$7.37 (+90.37%)
$2.46 (+470.33%)
$1.67 (+740.12%)
VTYX Analysts Opinion
VTYX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
VTYX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
VTYX Street Sentiment is extremely bullish and have positive views on the near-term outlook
VTYX has Extreme risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels
Jan 08, 2026
Initiate
Buy
UBS
Jan 07, 2026
Initiate
Buy
UBS
Nov 08, 2025
Reiterate
Overweight
Wells Fargo
Nov 08, 2025
Reiterate
Buy
Canaccord Genuity
Nov 05, 2025
Upgrade
Buy
HC Wainwright & Co.
VTYX Stock IQ
VTYX Latest Analysis
UBS Initiates Coverage of Ventyx Biosciences (VTYX) with Buy Recommendation. Fintel reports that on January 7 2026 UBS initiated coverage of Ventyx Biosciences (NasdaqGS:VTYX) with a Buy recommendation. Analyst Price Forecast Suggests 48.43% Upside
Thu Jan 8, 2026
Eli Lilly To Buy Ventyx Biosciences For About $1.2 Bln . (RTTNews) - Eli Lilly and Company (LLY) Wednesday said it has agreed to buy Ventyx Biosciences Inc. (VTYX) a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases.
Wed Jan 7, 2026
Wednesday Sector Leaders: Biotechnology Drugs. In trading on Wednesday biotechnology shares were relative leaders up on the day by about 3.4%. Leading the group were shares of Monte Rosa Therapeutics up about 49.5% and shares of Ventyx Biosciences up about 36.7% on the day.Also showing relative strength are drugs share
Wed Jan 7, 2026
Eli Lilly nears deal for Ventyx Biosciences at $14/share - WSJ.
Wed Jan 7, 2026
UBS initiates Ventyx Biosciences stock with Buy rating $20 price target.
Wed Jan 7, 2026
Ventyx Biosciences Launches On Rumored $1 Billion Eli Lilly Takeover. Shares of Ventyx Biosciences launched late Tuesday on reports Eli Lilly could be nearing a $1 billion deal to buy the company.The post Ventyx Biosciences Launches On Rumored $1 Billion Eli Lilly Takeover appeared first on Investor'.s Business Daily.
Tue Jan 6, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
VTYX Stock trends
VTYX Stock performance
VTYX Stock analysis
VTYX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.